OncoHost Receives Lab Permit From New York State DOH

Original source here

‍

NEW YORK – Israeli cancer proteomics firm OncoHost said Wednesday that it has received a laboratory permit from the New York State Department of Health Wadsworth Center.

With the permit, Binyamina-based OncoHost, which has a lab in Cary, North Carolina, can offer its ProphetNSCLC test for guiding therapy in lung cancer patients throughout New York state. The test is now available in all 50 US states.

Launched commercially in 2023, ProphetNSCLC measures thousands of plasma proteins in patient blood samples using SomaLogic's aptamer-based SomaScan technology. It assesses the likelihood that an individual with non-small cell lung cancer (NSCLC) will benefit from PD-1/PD-L1 inhibitor therapy.

"This permit is a significant step forward in making precision oncology accessible to more patients," OncoHost CEO Ofer Sharon said in a statement. "New York state maintains some of the most stringent laboratory certification requirements in the US, and meeting these standards underscores our scientific rigor, operational excellence, and dedication to clinical impact."

The New York permit adds to OncoHost's existing certifications under the Clinical Laboratory Improvement Amendments (CLIA) and its accreditation by the College of American Pathologists (CAP).

‍